Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
BERGER FRANKLIN M | Director | Dec 10 '24 | Sale | 2.85 | 359,606 | 1,023,475 | 451,897 | Dec 12 06:00 PM | Franklin Berger | Lead Independent Director | Dec 10 '24 | Proposed Sale | 2.85 | 359,606 | 1,023,475 | | Dec 10 05:17 PM | Sommadossi Jean-Pierre | President, CEO, and Chairman | Sep 17 '24 | Sale | 4.05 | 33,941 | 137,318 | 5,890,053 | Sep 19 08:02 PM | Sommadossi Jean-Pierre | President, CEO, and Chairman | Sep 18 '24 | Sale | 4.03 | 22,187 | 89,469 | 5,867,866 | Sep 19 08:02 PM | Sommadossi Jean-Pierre | President, CEO, and Chairman | Sep 19 '24 | Sale | 4.00 | 1,841 | 7,367 | 5,866,025 | Sep 19 08:02 PM | JPM Partners LLC | Affiliate | Sep 19 '24 | Proposed Sale | 4.00 | 1,841 | 7,367 | | Sep 19 04:22 PM | JPM Partners LLC | Affiliate | Sep 18 '24 | Proposed Sale | 4.03 | 22,187 | 89,469 | | Sep 18 04:09 PM | JPM Partners LLC | Affiliate | Sep 17 '24 | Proposed Sale | 4.05 | 33,941 | 137,318 | | Sep 17 04:16 PM | Polsky Bruce | Director | Jun 20 '24 | Sale | 3.49 | 17,544 | 61,144 | 65,606 | Jun 21 05:59 PM | Murphy Polly A. | Director | Jun 16 '24 | Option Exercise | 0.00 | 33,150 | 0 | 56,445 | Jun 18 05:00 PM | Lucidi Bruno | Director | Jun 16 '24 | Option Exercise | 0.00 | 33,150 | 0 | 83,150 | Jun 18 05:00 PM | BERGER FRANKLIN M | Director | Jun 16 '24 | Option Exercise | 0.00 | 33,150 | 0 | 811,503 | Jun 18 05:00 PM | Polsky Bruce | Director | Jun 16 '24 | Option Exercise | 0.00 | 33,150 | 0 | 83,150 | Jun 18 05:00 PM | Duncan Barbara Gayle | Director | Jun 16 '24 | Option Exercise | 0.00 | 33,150 | 0 | 33,150 | Jun 18 05:00 PM | Adams Jerome M. | Director | Jun 16 '24 | Option Exercise | 0.00 | 33,150 | 0 | 33,150 | Jun 18 05:00 PM | Sommadossi Jean-Pierre | President, CEO, and Chairman | Jun 05 '24 | Sale | 4.00 | 1,006 | 4,024 | 5,923,994 | Jun 07 06:34 PM | Corcoran Andrea | See Remarks | Feb 01 '24 | Sale | 3.84 | 15,843 | 60,915 | 670,208 | Feb 02 09:31 PM | Sommadossi Jean-Pierre | President, CEO, and Chairman | Feb 01 '24 | Sale | 3.85 | 56,910 | 218,819 | 116,557 | Feb 02 09:30 PM | Horga Maria Arantxa | Chief Medical Officer | Feb 01 '24 | Sale | 3.84 | 15,870 | 60,963 | 25,664 | Feb 02 09:29 PM | Foster Wayne | EVP, Chief Accounting Officer | Feb 01 '24 | Sale | 3.84 | 12,477 | 47,904 | 20,857 | Feb 02 09:26 PM | Vavricka John | Chief Commercial Officer | Feb 01 '24 | Sale | 3.84 | 11,819 | 45,420 | 21,515 | Feb 02 09:25 PM | Hammond Janet MJ | Chief Development Officer | Feb 01 '24 | Sale | 3.84 | 14,029 | 53,913 | 35,362 | Feb 02 09:24 PM |
|